Novanta Inc. (NOVT)
| Market Cap | 4.60B |
| Revenue (ttm) | 980.60M |
| Net Income (ttm) | 53.83M |
| Shares Out | 35.68M |
| EPS (ttm) | 1.47 |
| PE Ratio | 87.05 |
| Forward PE | 35.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 304,943 |
| Open | 131.78 |
| Previous Close | 132.78 |
| Day's Range | 127.53 - 131.78 |
| 52-Week Range | 98.27 - 149.95 |
| Beta | 1.65 |
| Analysts | Buy |
| Price Target | 144.00 (+11.6%) |
| Earnings Date | May 11, 2026 |
About NOVT
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment s... [Read more]
Financial Performance
In 2025, Novanta's revenue was $980.60 million, an increase of 3.30% compared to the previous year's $949.25 million. Earnings were $53.83 million, a decrease of -16.01%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NOVT stock is "Buy" and the 12-month stock price target is $144.0.
News
Novanta Inc. Announces Schedule of First Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 resul...
Novanta Joins NVIDIA Halos AI Systems Inspection Lab
BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) announced today that it has joined NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited inspection...
Novanta Earnings Call Transcript: Q4 2025
Record 2025 revenue and bookings, strong new product growth, and double-digit profit gains were achieved, though margins and cash flow were temporarily pressured by manufacturing transitions. 2026 guidance calls for 4–6% organic growth, margin expansion, and robust acquisition capacity.
Novanta Announces Financial Results for the Fourth Quarter and Full Year 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter 2025 resu...
Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Chuck Ravetto, Chief...
Novanta to Present at the J.P. Morgan 44th Annual Healthcare Conference on Wednesday, January 14, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Inc. Announces Pricing of $550,000,000 Tangible Equity Units Offering
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) ("Novanta" or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has ...
Novanta Inc. Announces Offering of Tangible Equity Units
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) ("Novanta" or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has ...
Novanta Earnings Call Transcript: Q3 2025
Q3 2025 results exceeded expectations with record revenue, strong margin expansion, and robust new product growth. Guidance calls for sequential revenue and profit growth into Q4 and 2026, led by advanced surgery and robotics, with regional manufacturing and acquisitions supporting resilience.
Novanta Announces Financial Results for the Third Quarter 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta to Present at Jefferies Global Healthcare Conference on Tuesday, November 18, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Hosts ISO event for Humanoid Robot Safety Standards
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced industrial OEMs, announced that it will host an International Organization for Standardizatio...
Novanta to Present at the Baird 2025 Global Industrial Conference on Tuesday, November 11, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, November 4, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2025 resul...
Novanta's Board of Directors Authorizes Additional $200 Million for Share Repurchase Program
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that its Board of Directo...
Novanta to Present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Earnings Call Transcript: Q2 2025
Q2 2025 results met or exceeded expectations, with strong growth in advanced surgery and robotics, robust new product momentum, and major design wins. Guidance calls for 2–4% revenue growth in 2025, with ongoing tariff and trade risks but sequential improvement expected in industrial and life sciences.
Novanta Announces Financial Results for the Second Quarter 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, August 5, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2025 resu...
Novanta to Present at the CJS Securities 25th Annual New Ideas Summer Conference on Thursday, July 10, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta to Present at Baird 2025 Global Consumer, Technology & Services Conference on Wednesday, June 4, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta to Present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Earnings Call Transcript: Q1 2025
Q1 2025 saw 2% organic revenue growth, strong cash flow, and robust new product launches, despite tariff headwinds and life science market weakness. Guidance for Q2 is $230M–$240M revenue, with EBITDA and EPS expected to remain solid.
Novanta Announces Financial Results for the First Quarter 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...